MTOR and renal carcinoma: Treatment with everolimus, the mTOR inhibitor which is clinically used for patients with renal cancer, successfully inhibited the activation of mTOR and the signaling of its downstream ribosomal protein S6 kinase β‐1 in OSPa and OS5K cells equally (Fig. S6).